Showing 2741-2750 of 2985 results for "".
- Wrinkle remover Revance files for $86 million IPOhttps://practicaldermatology.com/news/20140106-wrinkle_remover_revance_files_for_86_million_ipo/2459380/Revance Therapeutics Inc., a developer of next-generation versions of skin wrinkle eraser Botox, is seeking $86.25 million in an initial public offering.
- NYC's Eric Schweiger, MD Launches Book on Acne Treatmenthttps://practicaldermatology.com/news/20131230-nycs_eric_schweiger_md_launches_book_on_acne_treatment/2459384/New York City dermatologist Eric Schweiger, MD has launched his new book: 100 Acne Tips & Solutions: The Clear Clinic Guide to Perfect Skin, available December 2013 on
- Acneiform Eruptions Examined in New Bookhttps://practicaldermatology.com/news/20131223-acneiform_eruptions_examined_in_new_book/2459387/A new book that addresses the differential diagnosis of acne vulgaris and treatment of acne-like condition is now available through Springer. Acneiform Eruptions in Dermatology, edited by Practical Dermatology Board Member Joshua A. Zeichner, MD, offers expert guidance on acne and syst
- Syneron's Home-Use Hair Removal Systems Receive Expanded Indicationhttps://practicaldermatology.com/news/20131219-synerons_home-use_hair_removal_systems_receive_expanded_indication/2459390/The FDA has granted Syneron Medical Ltd. and Iluminage Beauty an expanded indication for me™ brand of home-use hair removal systems. The systems, which utilize Syneron's proprietary elos technology, are now indicated for permanent reduction in hair growth. The me™ brand is owned and sold by Iluminag
- Cosmetic Surgery Forum Kicks Off in Las Vegashttps://practicaldermatology.com/news/20131206-cosmetic_surgery_forum_kicks_off_in_las_vegas/2459397/The fifth annual Cosmetic Surgery Forum got underway yesterday in Las Vegas, Nevada, highlighted by varied educational sessions and discussion among faculty, attendees, and residents. Among the offerings from the first day were 75 resident presentations, practice management pearls, live injections,
- FDA Approves Varithena to Treat Varicose Veinshttps://practicaldermatology.com/news/20131127-fda_approved_varithena_to_treat_varicose_veins/2459401/The FDA recently approved BTG plc's Varithena (polidocanol injectable foam) for the treatment of patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system. V
- Valeant Pharmaceuticals Announces Appointment of Dr. Ari Kellen to Executive Management Teamhttps://practicaldermatology.com/news/20131125-valeant_pharmaceuticals_announces_appointment_of_dr_ari_kellen_to_executive_management_team/2459405/Valeant Pharmaceuticals International, Inc. announced that Dr. Ari Kellen has been named to Valeant's Executive Management Team and will assume the role of Executive Vice President/Company Group Chairman, effective January 1,
- Lithera Announces Appointment of Dr. Lincoln Krochmal as Chief Medical Officerhttps://practicaldermatology.com/news/20131121-lithera_announces_appointment_of_dr_lincoln_krochmal_as_chief_medical_officer/2459407/Lincoln Krochmal, MD was recently appointed as Chief Medical Officer of Lithera, Inc. According to the company, this appointment reflects the company's continued growth as it prepares to enter la
- Investigational Melanoma Agent Improves Survival in Phase III Trialhttps://practicaldermatology.com/news/20131120-investigational_melanoma_agent_improves_survival_in_phase_iii_trial/2459408/Interim results from a pivotal Phase III trial show that Amgen's investigational agent talimogene laherpaepvec increased overall survival in patients with unresected stage IIIB, IIIC, or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF). The study found that median ov
- Actelion Launches Valchlor to Treat Stage IA and IB Mycosis Fungoides-type Cutaneous T-cell Lymphomahttps://practicaldermatology.com/news/20131119-actelion_launches_valchlor_to_treat_stage_ia_and_ib_mycosis_fungoides-type_cutaneous_t-cell_lymphoma/2459409/The FDA approved Actelion's Valchlor (mechlorethamine), the first and only FDA-approved topical formulation of mechlorethamine. Valchlor, a gel that is applied topically once a day, is an alkylating drug indicated to treat p